The Latin America Hemophilia Management Market was worth $640 million in 2018 and estimated to be growing at a CAGR of 1.69%, to reach $700 million by 2023. Hemophilia is a genetic disorder which impairs body`s ability to control blood clotting. Hemophilia usually occurs in males and it is estimated that about 1 in 5000 males that are born each year contain hemophilia.
Hemophilia is categorized into three levels depending on its severity as severe, moderate and mild. About 80% of the hemophilia patients are considered to suffer from severe type. It is estimated that around 75% of the patients suffering from hemophilia do not receive adequate treatment.
Latin America Hemophilia market is driven by factors such as growing prevalence of the disease and increasing usage of recombinant product. Advancements in technology have brought novel oagulating factors which are also helping in the growth of the market. Rising investments into Research and developments is also a major factor supporting the market growth. However lack of awareness of the disease and high costs associated with the treatment of the disease are the major factors hindering the market growth. Advancements in gene therapy and approaching approval of drugs for treatment of hemophilia provide immense growth opportunities in the market.
Latin America market for Hemophilia management is analyzed on the basis of type of hemophilia and drug. By type it is further segmented into Hemophilia A and Hemophilia B. On the basis of drug it is further sub segmented into Octocogalfa, Nonacogalfa, Desmopressin and other drugs. Hemophilia A the largest segment accounting for approximately XX% and is also estimated to be the fastest growing segment due to a large number of people suffering from the disease Hemophilia
On the basis of geography Latin America hemophilia management market is analyzed under various regions namely Brazil, Argentina and Mexico. Latin America region provides lucrative growth opportunities for the haemophilia management market attributed to local government support and increasing focus of global players towards these countries. Within Latin America, Argentina is a major market accounting for a significant share within the region due to more open investment prospects
Some of the major companies discussed in the report are Biogen, Baxter International Inc., Pfizer Inc., Bayer Pharma AG, Novo Nordisk A/S, Grifols International SA, CSL Behring, Octapharma and Swedish Orphan Biovitrum AB
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5.1 BY Type
5.1.1 Hemophilia A
5.1.2 Hemophilia B
5.2 By Drug
5.2.1 Octocogalfa
5.2.2 Nonacogalfa
5.2.3 Desmopressin
5.2.4 Other drugs
6.1 Introduction
6.2 Brazil
6.3 Mexico
6.4 Argentina
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.1 Biogen
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Pfizer Inc.
8.3 Baxter International Inc.
8.4 Bayer Pharma AG
8.5 Novo Nordisk A/S
8.6 Grifols International SA
8.7 CSL Behring
8.8 Octapharma
8.9 Swedish Orphan Biovitrum AB
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
